# PepLib

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/peplib

- Industry: Pharmaceuticals
- Headquarters: Zhuzhou, China
- Website: www.peplib.cn
- Total disclosed funding: $107M
- Latest round: Series C (May 11, 2026)
- Investors on record: 19

## About

Based in Zhuzhou, China and established in 2017, Zonsen PepLib Biotech Inc., trading as PepLib, specializes in peptide drug development. The company has pursued strategic investments to enhance its product offerings. In May 2026, PepLib raised over CNY 300 million in Series C funding co-led by Lilly Asia Ventures and CDH Investments, with participation from Sherpa Healthcare Partners, Jifeng Ventures, Gaorong Ventures, Guotai Haitong Asset Management, Aier Healthcare Investment Group, XJSCI, Cowin Capital and Fortune Capital.
The company specializes in the development and provision of innovative biopharmaceutical solutions, focusing on peptide-based drug discovery. Its core offerings include proprietary pipelines for peptide therapeutics, the PV2 DNA Polymerase, the 1402 Quick Cloning Kit, and various cell lines. These products assist pharmaceutical companies and research institutions in drug discovery and development, primarily across North America and Europe.
The revenue model of the company is based on direct sales and partnerships with pharmaceutical and research entities. Transactions are facilitated through contracts for supplying flagship products, such as the PV2 DNA Polymerase and the 1402 Quick Cloning Kit, allowing clients to place bulk orders based on their research needs.
The Series C funding raised in May 2026 will be mainly used to accelerate the clinical advancement of the company's core pipeline projects, upgrade and iterate its AI drug development platform, build an international talent team, and expand its global cooperation layout.
In the future, the company will continue to focus on cutting-edge peptide drug technologies, accelerate the clinical and commercialization process of its core pipeline, and strive to bring more groundbreaking treatment options to patients worldwide as soon as possible.

## Funding rounds

- Series C, May 11, 2026, $44M — CDH Investments, Lilly Asia Ventures, Cowin Capital, Fortune Capital, Gaorong Ventures, Aier Healthcare Investment Group, Guotai Haitong Asset Management, Sherpa Healthcare Partners, Jifeng Ventures, XJSCI
- Series B, Jul 23, 2025, $14M — CDH Baifu Capital, Shangshan Capital, Cheng Du Sheng Nuo Biotec Co.,Ltd, XJSCI
- Series A, Apr 29, 2021, $34M — Cowin Capital, Fortune Capital, CAS Investment Management, ASB Ventures, Legend Star, Shanghai Hurrah Investment, CDH Baifu Capital
- Series A, Jul 26, 2019, $15M — Chongqing Boyi Equity Investment Fund Management, Hunan Xingxiang Investment Holding Group

## Investors

- Chongqing Boyi Equity Investment Fund Management — Series A
- Hunan Xingxiang Investment Holding Group (https://capitalatlas.ai/funds/hunan-xingxiang-investment-holding-group) — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A, Series C
- Fortune Capital — Series A, Series C
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series A
- ASB Ventures (https://capitalatlas.ai/funds/asb-ventures) — Series A
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- Shanghai Hurrah Investment — Series A
- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series A, Series B
- Shangshan Capital (https://capitalatlas.ai/funds/shangshan-capital) — Series B
- Cheng Du Sheng Nuo Biotec Co.,Ltd — Series B
- XJSCI — Series B, Series C
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series C
- Aier Healthcare Investment Group — Series C
- Guotai Haitong Asset Management — Series C
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series C
- Jifeng Ventures (https://capitalatlas.ai/funds/jifeng-ventures) — Series C